168 related articles for article (PubMed ID: 30542835)
21. Molecular pathways leading to oxidative stress-induced phosphorylation of Akt.
Lahair MM; Howe CJ; Rodriguez-Mora O; McCubrey JA; Franklin RA
Antioxid Redox Signal; 2006; 8(9-10):1749-56. PubMed ID: 16987028
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.
Misra UK; Pizzo SV
J Cell Biochem; 2012 May; 113(5):1488-500. PubMed ID: 22173835
[TBL] [Abstract][Full Text] [Related]
23. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
24. Protective effect of docosahexaenoic acid on lipotoxicity-mediated cell death in Schwann cells: Implication of PI3K/AKT and mTORC2 pathways.
Descorbeth M; Figueroa K; Serrano-Illán M; De León M
Brain Behav; 2018 Nov; 8(11):e01123. PubMed ID: 30264903
[TBL] [Abstract][Full Text] [Related]
25. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.
Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J
Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166
[TBL] [Abstract][Full Text] [Related]
26. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
27. mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer.
Hau AM; Leivo MZ; Gilder AS; Hu JJ; Gonias SL; Hansel DE
Cell Signal; 2017 Jan; 29():96-106. PubMed ID: 27777073
[TBL] [Abstract][Full Text] [Related]
28. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
29. Inflammation-induced mTORC2-Akt-mTORC1 signaling promotes macrophage foam cell formation.
Banerjee D; Sinha A; Saikia S; Gogoi B; Rathore AK; Das AS; Pal D; Buragohain AK; Dasgupta S
Biochimie; 2018 Aug; 151():139-149. PubMed ID: 29883748
[TBL] [Abstract][Full Text] [Related]
30. Serine Protease from
Chen Y; Tang Y; Tang Y; Yang Z; Ding G
Mar Drugs; 2019 Jun; 17(6):. PubMed ID: 31226829
[TBL] [Abstract][Full Text] [Related]
31. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
32. Avian reovirus p17 and σA act cooperatively to downregulate Akt by suppressing mTORC2 and CDK2/cyclin A2 and upregulating proteasome PSMB6.
Huang WR; Chi PI; Chiu HC; Hsu JL; Nielsen BL; Liao TL; Liu HJ
Sci Rep; 2017 Jul; 7(1):5226. PubMed ID: 28701787
[TBL] [Abstract][Full Text] [Related]
33. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
34. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
35. Lycopene Protects Keratinocytes Against UVB Radiation-Induced Carcinogenesis via Negative Regulation of FOXO3a Through the mTORC2/AKT Signaling Pathway.
Chen P; Xu S; Qu J
J Cell Biochem; 2018 Jan; 119(1):366-377. PubMed ID: 28585698
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W.
Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY
Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186
[TBL] [Abstract][Full Text] [Related]
37. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
38. SHORT syndrome due to a novel de novo mutation in PRKCE (Protein Kinase Cɛ) impairing TORC2-dependent AKT activation.
Alcantara D; Elmslie F; Tetreault M; Bareke E; Hartley T; ; Majewski J; Boycott K; Innes AM; Dyment DA; O'Driscoll M
Hum Mol Genet; 2017 Oct; 26(19):3713-3721. PubMed ID: 28934384
[TBL] [Abstract][Full Text] [Related]
39. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
40. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
